The role of pentraxin 3 and oxidative status in the prognosis of multiple myeloma

Basit Öğe Kaydı
dc.contributor.authorOguzman, Hamdi
dc.contributor.authorKacmaz, Murat
dc.date.accessioned2024-04-24T17:14:40Z
dc.date.available2024-04-24T17:14:40Z
dc.date.issued2024
dc.departmentDicle Üniversitesien_US
dc.description.abstractMultiple myeloma (MM) is a bone marrow malignancy characterized by plasma cell proliferation. It was aimed to investigate pentraxin 3 (PTX3) levels, oxidative/antioxidative status, and their correlation in MM. In the study, four groups were established, including newly diagnosed MM (NDMM), MM in remission (Rem-MM), relapsed/refractory MM (RRMM) patients, and a healthy control group. PTX3 levels were measured using enzyme-linked immunosorbent assay, and the total antioxidant status (TAS) and total oxidant status (TOS) were assessed with an autoanalyzer. The oxidative stress index (OSI) was calculated using the formula: OSI (arbitrary unit) = TOS (mu mol H2O2 Eq/L)/TAS (mmol Trolox Eq/L) x 100. The study involved comparing PTX3, TAS, TOS, and OSI levels among these four groups. PTX3 levels were significantly elevated in NDMM and RRMM groups compared to controls and the Rem-MM group (NDMM vs control; p < 0.001, NDMM vs Rem-MM; p < 0.001, RRMM vs control; p < 0.001, and RRMM vs Rem-MM; p = 0.006). TAS was higher in NDMM and RRMM groups versus controls (p = 0.009 and p < 0.001, respectively), and TOS was higher in rem-MM group versus NDMM and control groups (p < 0.001 and p = 0.016, respectively). OSI was higher in the Rem-MM group than in NDMM and RRMM groups (p < 0.001 and p = 0.009, respectively). Multivariate analysis confirmed associations between MM groups and PTX3 levels. Receiver operating characteristic analysis revealed high specificity (90%) and sensitivity (79%) for PTX3 in NDMM at a >0.56 ng/mL cut-off value. This study suggests that PTX3 levels may have diagnostic and prognostic potential in MM and its relationship with oxidative stress requires further exploration.en_US
dc.identifier.doi10.1177/10815589241235662
dc.identifier.endpage340en_US
dc.identifier.issn1081-5589
dc.identifier.issn1708-8267
dc.identifier.issue4en_US
dc.identifier.pmid38373952
dc.identifier.startpage333en_US
dc.identifier.urihttps://doi.org/10.1177/10815589241235662
dc.identifier.urihttps://hdl.handle.net/11468/18133
dc.identifier.volume72en_US
dc.identifier.wosWOS:001196750300006
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherSage Publications Ltden_US
dc.relation.ispartofJournal of Investigative Medicine
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectPtx3 Proteinen_US
dc.subjectOxidative Stressen_US
dc.subjectBone Marrow Neoplasmsen_US
dc.subjectHematologyen_US
dc.subjectBiomarkersen_US
dc.subjectMyeloproliferative Disordersen_US
dc.titleThe role of pentraxin 3 and oxidative status in the prognosis of multiple myelomaen_US
dc.titleThe role of pentraxin 3 and oxidative status in the prognosis of multiple myeloma
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu